drugset / Trial / NCT06892925
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
NaSingle-groupOpen-labelTreatment
Summary
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
Timeline
- Start
- 2025-06-14
- Primary completion
- 2026-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Lenvatinib | Small molecule | 8 mg | Oral |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |